Suppr超能文献

高密度脂蛋白成分、心力衰竭及其合并症

HDL Composition, Heart Failure, and Its Comorbidities.

作者信息

Diab Ahmed, Valenzuela Ripoll Carla, Guo Zhen, Javaheri Ali

机构信息

Division of Cardiology, Washington University School of Medicine, Saint Louis, MO, United States.

出版信息

Front Cardiovasc Med. 2022 Mar 8;9:846990. doi: 10.3389/fcvm.2022.846990. eCollection 2022.

Abstract

Although research on high-density lipoprotein (HDL) has historically focused on atherosclerotic coronary disease, there exists untapped potential of HDL biology for the treatment of heart failure. Anti-oxidant, anti-inflammatory, and endothelial protective properties of HDL could impact heart failure pathogenesis. HDL-associated proteins such as apolipoprotein A-I and M may have significant therapeutic effects on the myocardium, in part by modulating signal transduction pathways and sphingosine-1-phosphate biology. Furthermore, because heart failure is a complex syndrome characterized by multiple comorbidities, there are complex interactions between heart failure, its comorbidities, and lipoprotein homeostatic mechanisms. In this review, we will discuss the effects of heart failure and associated comorbidities on HDL, explore potential cardioprotective properties of HDL, and review novel HDL therapeutic targets in heart failure.

摘要

尽管历史上对高密度脂蛋白(HDL)的研究主要集中在动脉粥样硬化性冠状动脉疾病,但HDL生物学在心力衰竭治疗方面仍有未被开发的潜力。HDL的抗氧化、抗炎和内皮保护特性可能会影响心力衰竭的发病机制。与HDL相关的蛋白质,如载脂蛋白A-I和M,可能对心肌有显著的治疗作用,部分原因是通过调节信号转导通路和1-磷酸鞘氨醇生物学。此外,由于心力衰竭是一种以多种合并症为特征的复杂综合征,心力衰竭、其合并症和脂蛋白稳态机制之间存在复杂的相互作用。在这篇综述中,我们将讨论心力衰竭及相关合并症对HDL的影响,探索HDL潜在的心脏保护特性,并综述心力衰竭中HDL的新型治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ee/8958020/51c0a3b47553/fcvm-09-846990-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验